Neil Gregory Almstead sold $2.9M of PTCT
CHIEF TECHNICAL OPS OFFICER at PTC THERAPEUTICS, INC.. 35,572 shares at an average of $80.18, traded Nov 24, 2025, filed Nov 26, 2025.
Score components
- +15RoleOfficer
- +25Trade size$2.9M at market
- +10Share of holdings soldSold 35% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -8.9%, 3m -21.4%, 6m -18.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001578850-25-000006, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 24, 2025 | MOption exercise Common Stock10b5-1 | +1,900 | $18.01 | $34k | 102,525 | Nov 26, 2025 |
| Nov 24, 2025 | SOpen-market sale Common Stock10b5-1 | -1,900 | $80.14 | $152k | 100,625 | Nov 26, 2025 |
| Nov 24, 2025 | MOption exercise Common Stock10b5-1 | +1,650 | $33.02 | $54k | 102,275 | Nov 26, 2025 |
| Nov 24, 2025 | SOpen-market sale Common Stock10b5-1 | -1,650 | $80.14 | $132k | 100,625 | Nov 26, 2025 |
| Nov 24, 2025 | MOption exercise Common Stock10b5-1 | +4,715 | $18.01 | $85k | 105,340 | Nov 26, 2025 |
| Nov 24, 2025 | SOpen-market sale Common Stock10b5-1 | -4,715 | $80.15 | $378k | 100,625 | Nov 26, 2025 |
| Nov 24, 2025 | MOption exercise Common Stock10b5-1 | +21,206 | $33.02 | $700k | 121,831 | Nov 26, 2025 |
| Nov 24, 2025 | SOpen-market sale Common Stock10b5-1 | -21,206 | $80.19 | $1.7M | 100,625 | Nov 26, 2025 |
| Nov 24, 2025 | MOption exercise Common Stock10b5-1 | +6,101 | $33.02 | $201k | 106,726 | Nov 26, 2025 |
| Nov 24, 2025 | SOpen-market sale Common Stock10b5-1 | -6,101 | $80.17 | $489k | 100,625 | Nov 26, 2025 |
| Nov 24, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,900 | $0.00 | $0 | 15,600 | Nov 26, 2025 |
| Nov 24, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,650 | $0.00 | $0 | 70,850 | Nov 26, 2025 |
| Nov 24, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -4,715 | $0.00 | $0 | 10,885 | Nov 26, 2025 |
| Nov 24, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -21,206 | $0.00 | $0 | 49,644 | Nov 26, 2025 |
| Nov 24, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -6,101 | $0.00 | $0 | 11,399 | Nov 26, 2025 |
Related signals
Other insiders at PTC THERAPEUTICS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| Pro nowfree Oct 20, 2026 | PTC THERAPEUTICS, INC. | Mark Elliott Boulding EXEC. VP AND CLO | $12k 192 shares | -0% | |
| Pro nowfree Oct 16, 2026 | PTC THERAPEUTICS, INC. | Michael Schmertzler director | $158k 2,500 shares | -0% | |
| 6Weak | PTC THERAPEUTICS, INC. | Mark Elliott Boulding EXEC. VP AND CLO | $133k 2,073 shares | -2% | |
| 27Weak | PTC THERAPEUTICS, INC. | Glenn Steele Jr Md Phd director | $782k 12,000 shares | -35% | |
| 28Weak | PTC THERAPEUTICS, INC. | Michael Schmertzler director | $1.3M 20,000 shares | -2% | |
| 20Weak | PTC THERAPEUTICS, INC. | Michael Schmertzler director | $1.4M 20,000 shares | -1% | |
| 28Weak | PTC THERAPEUTICS, INC. | Michael Schmertzler director | $1.8M 25,000 shares | -2% | |
| 28Weak | PTC THERAPEUTICS, INC. | Michael Schmertzler director | $1.8M 25,000 shares | -2% | |
| 7Weak | PTC THERAPEUTICS, INC. | Mark Elliott Boulding EXEC. VP AND CLO | $204k 2,813 shares | -3% | |
| 34Weak | PTC THERAPEUTICS, INC. | Matthew B. Klein CHIEF EXECUTIVE OFFICER | $706k 10,292 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.